CytomX

$6.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (+0.91%) As of 2:17 PM EDT today

Why Robinhood?

You can buy or sell CytomX and other stocks, options, and ETFs commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Read More The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. The listed name for CTMX is CytomX Therapeutics, Inc. Common Stock.

Employees
158
Headquarters
South San Francisco, California
Founded
2010
Market Cap
305.33M
Price-Earnings Ratio
Dividend Yield
Average Volume
359.57K
High Today
$6.70
Low Today
$6.44
Open Price
$6.57
Volume
161.55K
52 Week High
$15.44
52 Week Low
$3.60

Collections

CTMX Earnings

-$0.79
-$0.44
-$0.09
$0.26
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 5, After Hours

You May Also Like